Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

OBJECTIVE: Tofacitinib is an oral JAK inhibitor that is used for the treatment of rheumatoid arthritis (RA). In previous clinical trials of tofacitinib, a Disease Activity Score in 28 joints (DAS28)–based analysis was used to assess outcomes. In this study, remission rates according to various remis...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S., Aletaha, Daniel, Gruben, David, Zwillich, Samuel H., Krishnaswami, Sriram, Mebus, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396306/
https://www.ncbi.nlm.nih.gov/pubmed/27907269
http://dx.doi.org/10.1002/art.39996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396306/
https://www.ncbi.nlm.nih.gov/pubmed/27907269
http://dx.doi.org/10.1002/art.39996

Ejemplares similares